99mTc-HMPAO as a tumour blood flow agent.
The cerebral blood flow agent, 99mTc-HMPAO ('CeretecTM') has been investigated to see if it can be used to estimate tumour blood flow. Its distribution in Balb/c mice bearing either a subcutaneously implanted sarcoma or a plasmacytoma has been shown to be similar to that of 86RbCl. The changes in peripheral blood flow caused by the beta-blocker, propranolol, and by Nembutal anaesthesia, are manifested equally by 99mTc-HMPAO and 86Rb. We conclude, therefore, that HMPAO may be useful in estimating tumour perfusion.
D000818:Animals; D002712:Chlorides; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply* / Q000000981:diagnostic imaging; D009942:Organometallic Compounds / Q000378:metabolism; D010091:Oximes / Q000378:metabolism; D011868:Radioisotopes; D011877:Radionuclide Imaging; D012413:Rubidium; D019690:Technetium Tc 99m Exametazime; D014018:Tissue Distribution
D002712:Chlorides; D009942:Organometallic Compounds; D010091:Oximes; D011868:Radioisotopes; D019690:Technetium Tc 99m Exametazime; D012413:Rubidium; C032710:rubidium chloride